1. Home
  2. LGND vs LMAT Comparison

LGND vs LMAT Comparison

Compare LGND & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • LMAT
  • Stock Information
  • Founded
  • LGND 1987
  • LMAT 1983
  • Country
  • LGND United States
  • LMAT United States
  • Employees
  • LGND N/A
  • LMAT N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • LMAT Medical/Dental Instruments
  • Sector
  • LGND Health Care
  • LMAT Health Care
  • Exchange
  • LGND Nasdaq
  • LMAT Nasdaq
  • Market Cap
  • LGND 2.3B
  • LMAT 2.4B
  • IPO Year
  • LGND 1992
  • LMAT 2006
  • Fundamental
  • Price
  • LGND $120.43
  • LMAT $90.93
  • Analyst Decision
  • LGND Strong Buy
  • LMAT Buy
  • Analyst Count
  • LGND 6
  • LMAT 7
  • Target Price
  • LGND $145.00
  • LMAT $92.83
  • AVG Volume (30 Days)
  • LGND 107.6K
  • LMAT 176.2K
  • Earning Date
  • LGND 11-07-2024
  • LMAT 10-31-2024
  • Dividend Yield
  • LGND N/A
  • LMAT 0.71%
  • EPS Growth
  • LGND 160.46
  • LMAT 49.21
  • EPS
  • LGND 2.47
  • LMAT 1.82
  • Revenue
  • LGND $152,422,000.00
  • LMAT $213,029,000.00
  • Revenue This Year
  • LGND $26.86
  • LMAT $16.04
  • Revenue Next Year
  • LGND $13.16
  • LMAT $9.62
  • P/E Ratio
  • LGND $48.80
  • LMAT $49.88
  • Revenue Growth
  • LGND N/A
  • LMAT 14.81
  • 52 Week Low
  • LGND $67.53
  • LMAT $52.88
  • 52 Week High
  • LGND $129.90
  • LMAT $109.58
  • Technical
  • Relative Strength Index (RSI)
  • LGND 52.94
  • LMAT 31.92
  • Support Level
  • LGND $113.39
  • LMAT $88.77
  • Resistance Level
  • LGND $124.03
  • LMAT $102.66
  • Average True Range (ATR)
  • LGND 5.31
  • LMAT 2.84
  • MACD
  • LGND -0.50
  • LMAT -1.74
  • Stochastic Oscillator
  • LGND 48.65
  • LMAT 11.70

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Share on Social Networks: